3Leibovich BC, Pantuck A J, Mattheu HT,et al. Current staging of venal cell canrcinama[J]. Urol Clin North Am,2003,30( 1 ) : 481 - 497.
4Rouviere O,Bouvier R, Negrier S,et al. Nonmetastatie renal cell carcinoma: is it really possible to defne rational guidelines for post-treatment follow up[ J ]. Nat Clin Pratt Oncol,2006,3 ( 3 ) : 200 -213.
5Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectom in patients with metastatic renal cancer. A combined analysis[ J]. J Urol,2004,171 (12) :1071 - 1076.
6Hofmann HS, Meef H, Krohe K, et al. Prognostic factors and survival after pulmonary resction of metastatic renal cell carcinoma [J]. Eur Urol,2005,48(1 ) :77 -81.
7Zagoria R J, Hawkins AD, Clark PE, et al. Percutaneous CT- guided radiofrequency ablation of renal neoplasms : factors influencing success[J]. Am J Roentgenol, 2004 ,183( 1 ) :201 -207.
8Gervais DA, McGovern FJ, Arellano RS, et al. Radiofrequency ablation of renal cell carcinoma I Indications results and role patient managetnr over a 6-year period and ablation of 100 tumors[ J ]. Am J Roentgenol,2005,185( 1 ) :64 -71.
9McDougal WS,Gervais DA, Mcgovern FJ, et al. Long-term follow up of patients with renal cell carcinoma treated by radiofrequency ablation with curative intent[J]. J Urol,2005,174( 1 ) :61 -63.
10Farrell MA, Charboneau WJ, Dimareo DS. Image-guided radio frequency ablation of solid renal tumors [ J ]. Am J Roentgenol, 2003,180(4) :1509 - 1573.
2Takahashi H,Shibuya M.The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions.Clin Sci (Lond),2005,109:227-241.
4Neufeld G,Kessler O,Herzog Y.The interaction of Neuropilin-1 and Neuropilin-2 with tyrosine2kinase receptors for VEGF.Adv Exp Med Biol,2002,515:81-90.
5Gerber HP,Ferrara N.The role of VEGF in normal and neoplastic hematopoiesis.J Mol Med,2003,81:20-31.
2Motzer RJ,Agarwal N,Beard C,et al.Kidney cancer,the National Comprehensive Cancer Network(NCCN) clincal practice guidelines[J].Oncology,2009,1:3.
3Motzer RJ,Hutson TE,Tomczak P,et al.Sunitinib versus interferon alfa in metastaic renal-cell carcincma[J].N Engl J Med,2007,356(2):115-124.
4Hemberg M.Interferor alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma[J].J Clin Oncol,2003,21(20):3770-3774.
6Chow E,Harris K,Fan G,et al.Palliative radiotherapy trial for bone metastases:a systematic review[J].J Clin Oncol,2007,25(11):1423-1436.
7Hillner BE,Ingle JN,Chlebowski RT,et al.American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer[J].J Clin Oncol,2003,21(21):4042-4057.
8James R.Berenson:Recommendations for zoledronic acid treatment of patients with bone metastases[J].The Oncologist,2005,10(1):52-62.
9Leibovich BC,Pantuck AJ,Mattheu HT,et al.Current staging of renal cell canrcinama[J].Urol Clin North Am,2003,30(1):481-497.
10Rouviere O,Bouvier R,Negrier S,et al.Nonmetastatic renal cell carcinoma:is it really possible to define rational guidelines for post-treatment follow up[J].Nat Clin Pract Oncol,2006,3(3):200-213.
